Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD33 CAR NK Cell Therapy in Relapsed/Refractory AML
NCT05008575Phase 1Unknown
- Sponsor
- Xinqiao Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Anti-CD33 CAR-NK cells in acute myeloid leukemia (AML), sponsored by Xinqiao Hospital. Primary endpoints: Overall Remission Rate at 4 weeks and Incidence of Dose Limiting Toxicity at 4 weeks. Status: unknown.
02
Drugs
Anti-CD33 CAR-NK cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05008575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008575.